Non-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivo
The clinical potential of PARP-1 inhibitors has been recognized >10 years ago, prompting intensive research on their pharmacological application in several branches of medicine, particularly in oncology. However, natural or acquired resistance of tumors to known PARP-1 inhibitors poses a serious...
Main Authors: | Colin Thomas, Yingbiao Ji, Niraj Lodhi, Elena Kotova, Aaron Dan Pinnola, Konstantin Golovine, Peter Makhov, Kate Pechenkina, Vladimir Kolenko, Alexei V. Tulin |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-11-01
|
Series: | EBioMedicine |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S235239641630456X |
Similar Items
-
Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy
by: Bijay Singh, et al.
Published: (2020-11-01) -
Structurally unique PARP‐1 inhibitors for the treatment of prostate cancer
by: Ali Divan, et al.
Published: (2020-04-01) -
In Vivo Level of Poly(ADP-ribose)
by: Masanao Miwa, et al.
Published: (2018-05-01) -
Automodified Poly(ADP-Ribose) Polymerase Analysisto Monitor DNA Damagein Peripheral Lymphocytes of Floriculturists Occupationally Exposed to Pesticides
by: Serena Imperato, et al.
Published: (2019-02-01) -
Molecular Insights into Poly(ADP-ribose) Recognition and Processing
by: Ivan Ahel, et al.
Published: (2012-12-01)